NASDAQ:VRNA Verona Pharma (VRNA) Stock Price, News & Analysis $34.66 +0.63 (+1.85%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Verona Pharma Stock (NASDAQ:VRNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Verona Pharma alerts:Sign Up Key Stats Today's Range$33.67▼$34.7250-Day Range$22.62▼$34.6652-Week Range$11.39▼$34.74Volume740,531 shsAverage Volume913,448 shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/APrice Target$39.33Consensus RatingBuy Company OverviewVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Verona Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreVRNA MarketRank™: Verona Pharma scored higher than 47% of companies evaluated by MarketBeat, and ranked 685th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerona Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Verona Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verona Pharma are expected to grow in the coming year, from ($2.07) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -22.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -22.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 11.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verona Pharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.02% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Verona Pharma has recently decreased by 9.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.02% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Verona Pharma has recently decreased by 9.49%, indicating that investor sentiment is improving significantly. News and Social Media3.9 / 5News Sentiment1.04 News SentimentVerona Pharma has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Verona Pharma this week, compared to 3 articles on an average week.Search Interest16 people have searched for VRNA on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows8 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Verona Pharma is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verona Pharma's insider trading history. Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Stock News HeadlinesVerona Pharma (NASDAQ:VRNA) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comTruist Financial Increases Verona Pharma (NASDAQ:VRNA) Price Target to $44.00October 9, 2024 | americanbankingnews.comUnlock the Secret to Earning Consistent Income from Stocks Under $30!Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!October 17, 2024 | Darwin (Ad)Wells Fargo Initiates Coverage of Verona Pharma plc - Depositary Receipt () (VRNA) with Overweight RecommendationOctober 4, 2024 | msn.comVerona Pharma reiterates stock target, buy rating with positive COPD dataOctober 3, 2024 | investing.comVerona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024September 30, 2024 | globenewswire.comRitedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*September 17, 2024 | finance.yahoo.comInsider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)September 14, 2024 | finance.yahoo.comSee More Headlines VRNA Stock Analysis - Frequently Asked Questions How have VRNA shares performed this year? Verona Pharma's stock was trading at $19.88 at the beginning of 2024. Since then, VRNA stock has increased by 74.3% and is now trading at $34.66. View the best growth stocks for 2024 here. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) released its earnings results on Thursday, August, 8th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.53. When did Verona Pharma IPO? Verona Pharma (VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. Who are Verona Pharma's major shareholders? Top institutional investors of Verona Pharma include Claro Advisors LLC (0.01%) and GAMMA Investing LLC. Insiders that own company stock include David Zaccardelli, Mark W Hahn, Orbimed Advisors Llc, Kathleen A Rickard, Claire Poll, David R Ebsworth, Martin Edwards and Lisa Deschamps. View institutional ownership trends. How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/08/2024Today10/17/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRNA CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$39.33 High Stock Price Target$50.00 Low Stock Price Target$33.00 Potential Upside/Downside+13.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.38% Return on Assets-37.88% Debt Debt-to-Equity Ratio0.72 Current Ratio8.61 Quick Ratio8.61 Sales & Book Value Annual Sales$460,000.00 Price / Sales6,023.31 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book11.18Miscellaneous Outstanding Shares79,940,000Free Float77,336,000Market Cap$2.77 billion OptionableOptionable Beta0.44 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:VRNA) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.